Rhelion Life Sciences Corp.
TRUFF
$0.02
$0.008.42%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 629.40K | 907.20K | 547.50K | 940.40K | 591.90K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 629.40K | 907.20K | 547.50K | 940.40K | 591.90K |
| Cost of Revenue | 299.70K | 650.50K | 309.90K | 617.20K | 367.60K |
| Gross Profit | 329.80K | 256.70K | 237.60K | 323.20K | 224.20K |
| SG&A Expenses | 1.11M | 1.11M | 958.90K | 1.15M | 953.70K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | 0.00 |
| Total Operating Expenses | 1.41M | 1.77M | 1.27M | 1.77M | 1.32M |
| Operating Income | -784.70K | -858.90K | -723.30K | -826.50K | -729.40K |
| Income Before Tax | -2.47M | -1.03M | -894.10K | -771.00K | -1.15M |
| Income Tax Expenses | -168.60K | -20.50K | -30.20K | -15.20K | -57.50K |
| Earnings from Continuing Operations | -2.30M | -1.01M | -863.90K | -755.80K | -1.09M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 481.90K | 23.20K | 16.80K | 12.50K | 117.00K |
| Net Income | -1.82M | -989.10K | -847.10K | -743.30K | -973.80K |
| EBIT | -784.70K | -858.90K | -723.30K | -826.50K | -729.40K |
| EBITDA | -1.42M | -808.80K | -668.40K | -773.40K | -608.20K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 424.64M | 417.59M | 412.25M | 411.87M | 405.82M |
| Average Diluted Shares Outstanding | 424.64M | 417.59M | 412.25M | 411.87M | 405.82M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |